HK1024629A1 - Monoesters of probucol for the treatment of cardiovascular and inflammatory disease. - Google Patents

Monoesters of probucol for the treatment of cardiovascular and inflammatory disease.

Info

Publication number
HK1024629A1
HK1024629A1 HK00103938A HK00103938A HK1024629A1 HK 1024629 A1 HK1024629 A1 HK 1024629A1 HK 00103938 A HK00103938 A HK 00103938A HK 00103938 A HK00103938 A HK 00103938A HK 1024629 A1 HK1024629 A1 HK 1024629A1
Authority
HK
Hong Kong
Prior art keywords
treatment
cardiovascular
probucol
monoesters
inflammatory disease
Prior art date
Application number
HK00103938A
Other languages
English (en)
Inventor
Patricia K Somers
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Publication of HK1024629A1 publication Critical patent/HK1024629A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
HK00103938A 1997-05-14 2000-06-29 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease. HK1024629A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4702097P 1997-05-14 1997-05-14
PCT/US1998/009773 WO1998051289A2 (en) 1997-05-14 1998-05-14 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease

Publications (1)

Publication Number Publication Date
HK1024629A1 true HK1024629A1 (en) 2000-10-20

Family

ID=21946634

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00103938A HK1024629A1 (en) 1997-05-14 2000-06-29 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease.
HK00105042A HK1025947A1 (en) 1997-05-14 2000-08-14 A monoether of probucol and methods for the inhibition of the expression of vcam-1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK00105042A HK1025947A1 (en) 1997-05-14 2000-08-14 A monoether of probucol and methods for the inhibition of the expression of vcam-1.

Country Status (26)

Country Link
US (9) US6121319A (ja)
EP (2) EP0994853B1 (ja)
JP (4) JP2001524986A (ja)
KR (5) KR20010012504A (ja)
CN (7) CN1977836A (ja)
AT (3) ATE304350T1 (ja)
AU (2) AU747801C (ja)
BR (2) BR9809793A (ja)
CA (3) CA2428130A1 (ja)
CY (1) CY1107645T1 (ja)
CZ (4) CZ301302B6 (ja)
DE (3) DE69829966T2 (ja)
DK (2) DK0981343T3 (ja)
EA (5) EA009370B1 (ja)
ES (3) ES2241139T3 (ja)
HK (2) HK1024629A1 (ja)
HU (2) HU226611B1 (ja)
ID (2) ID29158A (ja)
IL (7) IL164568A0 (ja)
NO (3) NO327603B1 (ja)
NZ (2) NZ501069A (ja)
PL (2) PL194329B1 (ja)
PT (1) PT1464639E (ja)
SK (4) SK286674B6 (ja)
TR (2) TR199902803T2 (ja)
WO (2) WO1998051289A2 (ja)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
ATE304350T1 (de) * 1997-05-14 2005-09-15 Atherogenics Inc Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1017375A2 (en) * 1997-09-24 2000-07-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
US6887712B1 (en) * 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US7361684B2 (en) * 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
AU4765101A (en) * 2000-03-21 2001-10-03 Atherogenics Inc Thioketals and thioethers for inhibiting the expression of vcam-1
CA2404044A1 (en) 2000-04-11 2001-10-18 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
NZ523443A (en) * 2000-06-20 2004-11-26 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US6545007B2 (en) 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
AUPQ872800A0 (en) * 2000-07-12 2000-08-03 Heart Research Institute, The Compositions and methods for treating cardiovascular disorders
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
EP1385501A2 (en) * 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
CA2464717A1 (en) * 2001-10-25 2003-05-15 Atherogenics, Inc. Compounds and methods for treating transplant rejection
AU2002352826B2 (en) * 2001-11-09 2009-05-28 Atherogenics, Inc. Methods of reversing and preventing cardiovascular pathologies
MXPA04005864A (es) 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
ITMI20020597A1 (it) 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US6960683B2 (en) * 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
CA2501685A1 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
SG142207A1 (en) * 2003-01-13 2008-05-28 Atherogenics Inc Process of preparing esters and ethers of probucol and derivatives thereof
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
WO2004108094A2 (en) 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005025492A2 (en) * 2003-07-07 2005-03-24 Emory University Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
JP2007509054A (ja) * 2003-10-17 2007-04-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 血管健康を促進するシリルフェノール
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1689706B1 (en) * 2003-11-14 2017-01-11 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
EP1689707A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Novel compounds for the treatment of obesity
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
WO2005112914A2 (en) * 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20070260087A1 (en) * 2004-04-20 2007-11-08 Atherogenics, Inc. Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
JP2008505097A (ja) * 2004-07-01 2008-02-21 アセロジエニクス・インコーポレイテツド 糖尿病性血管疾患を治療するための化合物および方法
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
SG163577A1 (en) 2004-12-03 2010-08-30 Schering Corp Substituted piperazines as cb1 antagonists
EP1844009A4 (en) * 2004-12-17 2010-04-21 Roland O Stocker COMPOSITIONS AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
AU2006240083A1 (en) 2005-04-21 2006-11-02 Atherogenics, Inc. Process for the separation of probucol derivatives
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
RU2008133381A (ru) 2006-01-18 2010-02-27 Шеринг Корпорейшн (US) Модуляторы каннабиноидного рецептора
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
WO2008118946A1 (en) * 2007-03-27 2008-10-02 Atherogenics, Inc. Methods and compositions using certain phenolic derivatives for the treatment of diabetes
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2008130718A1 (en) 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
US20100324328A1 (en) * 2007-06-26 2010-12-23 Astrazeneca Ab Process For Isolating Mono-Carboxy Substituted Probucol Derivatives
EP2170847A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
RU2010102478A (ru) * 2007-06-28 2011-08-10 Интэрвэт Интэрнэшнл Б.Ф. (NL) Замещенные пиперазины как антагонисты св1
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US9173997B2 (en) 2007-10-02 2015-11-03 Medimop Medical Projects Ltd. External drug pump
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US8907095B2 (en) 2007-10-22 2014-12-09 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119
WO2009138437A1 (en) * 2008-05-13 2009-11-19 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US20100145305A1 (en) * 2008-11-10 2010-06-10 Ruth Alon Low volume accurate injector
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2382203B1 (en) 2008-12-23 2015-01-14 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
AU2009330206A1 (en) 2008-12-23 2011-07-07 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modttlators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8152779B2 (en) * 2008-12-30 2012-04-10 Medimop Medical Projects Ltd. Needle assembly for drug pump
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
JP2012520343A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害治療のための併用療法
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
SI2437606T1 (sl) 2009-05-18 2016-10-28 Telomerase Activation Sciences, Inc. Sestavki in postopki za povečanje telomerazne aktivnosti
US8157769B2 (en) 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
EP2504010A4 (en) 2009-11-23 2013-04-17 Merck Sharp & Dohme Fused Bicyclic Pyrimidine Derivatives and Methods of Use Therefor
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
EP2569031B1 (en) 2010-05-10 2017-10-11 Medimop Medical Projects Ltd. Low volume accurate injector
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
WO2014134539A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
WO2016196934A1 (en) 2015-06-04 2016-12-08 Medimop Medical Projects Ltd. Cartridge insertion for drug delivery device
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10086145B2 (en) 2015-09-22 2018-10-02 West Pharma Services Il, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
CN113648488B (zh) 2015-10-09 2024-03-29 西医药服务以色列分公司 至预填充的流体储存器的弯曲流体路径附加装置
WO2017127215A1 (en) 2016-01-21 2017-07-27 Medimop Medical Projects Ltd. Needle insertion and retraction mechanism
JP6885960B2 (ja) 2016-01-21 2021-06-16 ウェスト ファーマ サービシーズ イスラエル リミテッド 視覚的インジケータを有する薬剤デリバリデバイス
JP6513297B2 (ja) 2016-01-21 2019-05-22 ウェスト ファーマ サービシーズ イスラエル リミテッド 自動注射器、受け入れフレーム及び自動注射器におけるカートリッジの接続方法
US11389597B2 (en) 2016-03-16 2022-07-19 West Pharma. Services IL, Ltd. Staged telescopic screw assembly having different visual indicators
US10376647B2 (en) 2016-03-18 2019-08-13 West Pharma. Services IL, Ltd. Anti-rotation mechanism for telescopic screw assembly
WO2017210448A1 (en) 2016-06-02 2017-12-07 Medimop Medical Projects Ltd. Three position needle retraction
US9650332B1 (en) * 2016-06-16 2017-05-16 Yong Xu Prodrug of probucol and method for preparing the same
JP6869327B2 (ja) 2016-08-01 2021-05-12 ウェスト ファーマ サービシーズ イスラエル リミテッド 回転防止カートリッジ
EP3490635B1 (en) 2016-08-01 2021-11-17 West Pharma. Services Il, Ltd. Partial door closure prevention spring
CN106905208B (zh) * 2017-02-27 2018-09-07 江西瑞雅药业有限公司 普罗布考前药及其制备方法和药物组合物
JP6921997B2 (ja) 2017-05-30 2021-08-18 ウェスト ファーマ サービシーズ イスラエル リミテッド ウェアラブル注射器のモジュラ駆動トレイン
WO2019126421A1 (en) 2017-12-22 2019-06-27 West Pharma. Services Il., Ltd. Injector usable with different dimension cartridges
CN108299263B (zh) * 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179701A (en) * 1962-05-14 1965-04-20 Shell Oil Co (3, 5-dialkyl-4-hydroxyphenyl) (3, 5-dialkyl-4-hydroxybenzyl) sulfides
US4115590A (en) * 1964-02-26 1978-09-19 Ethyl Corporation Binuclear phenols for reducing plasma lipid levels
GB1136539A (en) * 1966-12-13 1968-12-11 Uniroyal Inc Phenolic sulphides
US3485843A (en) * 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
GB1199871A (en) * 1967-05-11 1970-07-22 Consolidation Coal Co Improvements in or relating to Sulfur-Containing Bisphenols
GB1148550A (en) * 1967-12-02 1969-04-16 Uniroyal Inc Substituted benzylphenyl sulfides and their use as antioxidants
US3479407A (en) * 1968-11-06 1969-11-18 Consolidation Coal Co Sulfurization of 2,6-di-tert-butylphenol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
DE2104524C3 (de) 1970-09-16 1980-08-07 Veb Kombinat Umformtechnik Herbert Warnke Erfurt, Ddr 5000 Erfurt Hydraulische Überlastsicherung
FR2130975A5 (en) * 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) * 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2134810A5 (en) * 1971-04-21 1972-12-08 Aries Robert Bis-(3-alkyl-5-t-alkyl-4-(thiazole-5-carboxy)phenylthio) alcanes - - with hypocholesterolaemic and hypolipaemic activity
FR2140769A5 (en) * 1971-06-07 1973-01-19 Aries Robert Benzofuryloxy alkanoic derivs of probucol - hypocholesterolemic and hypolipemic agents
FR2140771A5 (en) * 1971-06-07 1973-01-19 Aries Robert Tetralinyl phenoxy alkanoic esters - of bis hydroxyphenylthio alkanes, hypolipemics etc
FR2168137A1 (en) * 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
JPS4975552A (ja) * 1972-11-20 1974-07-20
US3952064A (en) * 1973-03-12 1976-04-20 Crown Zellerbach Corporation Process for producing mercaptophenols
US4029812A (en) * 1976-02-18 1977-06-14 The Dow Chemical Company Novel hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4968514A (en) * 1984-12-11 1990-11-06 Forbes Polytech, Inc. Beer bottle with fully reacted thermoplastic polyurethane crown capliner
AU584669B2 (en) * 1985-02-04 1989-06-01 G.D. Searle & Co. Novel disubstituted 4-hydroxyphenylthio anilides
US4679520A (en) 1985-06-10 1987-07-14 Harken Olaf T Mainsail reefing and furling device and method
DE3530256A1 (de) 1985-08-23 1987-02-26 Merrell Dow Pharma Verwendung von probucol bei der behandlung von herzarrhythmie
US4755524A (en) * 1986-01-31 1988-07-05 G. D. Searle & Co. Novel phenolic thioethers as inhibitors of 5-lipoxygenase
DE3625279A1 (de) 1986-07-25 1988-02-04 Merrell Dow Pharma Verwendung von probucol zur vorbeugung und behandlung von erkrankungen des herzens
US4975467A (en) 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
EP0292660B1 (en) * 1987-03-17 1992-03-18 Merrell Dow Pharmaceuticals Inc. Alkylidenedithiobis (substituted) phenols for inhibiting interleukin-1 release and for alleviating interleukin-1 mediated conditions
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
NZ226621A (en) * 1987-11-13 1991-12-23 Riker Laboratories Inc Di-tert butyl phenols substituted by alkoxy, benzyloxy, or benzylthio groups; pharmaceutical compositions containing them
US4968710A (en) 1987-11-13 1990-11-06 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
US5066822A (en) 1987-11-13 1991-11-19 Riker Laboratories, Inc Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group
CH675422A5 (ja) 1988-03-31 1990-09-28 Symphar Sa
JP2754039B2 (ja) * 1988-06-24 1998-05-20 塩野義製薬株式会社 ジ―ｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
JP2627003B2 (ja) * 1989-01-25 1997-07-02 塩野義製薬株式会社 ジーｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
US5527945A (en) 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
JP3065636B2 (ja) * 1989-06-29 2000-07-17 塩野義製薬株式会社 ［ジ―ｔｅｒｔ―ブチル（ヒドロキシ）フェニルチオ］置換ヒドロキサム酸誘導体
CA2017956A1 (en) * 1989-07-06 1991-01-06 Werner Bollag Use of retinoids
DE3929913A1 (de) 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
US5115250A (en) * 1990-01-12 1992-05-19 Hewlett-Packard Company Wiper for ink-jet printhead
US5061734A (en) 1990-05-09 1991-10-29 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5112870A (en) 1990-05-09 1992-05-12 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5085777A (en) * 1990-08-31 1992-02-04 E. I. Du Pont De Nemours And Company Reverse osmosis membranes of polyamideurethane
FR2666583B1 (fr) * 1990-09-06 1994-09-09 Adir Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
GB9115951D0 (en) 1991-07-24 1991-09-11 Pfizer Ltd Indoles
EP0625138B1 (de) 1992-02-05 1999-06-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonistischer wirkung
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
US5310949A (en) 1992-09-02 1994-05-10 Merck & Co., Inc. Cholesterol lowering compounds
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
US5821260A (en) * 1992-10-30 1998-10-13 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
US5585235A (en) 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
FR2704224B1 (fr) * 1993-04-20 1995-08-25 Adir Nouveaux acides et esters phénoxy isobutyriques substitués.
JPH06312978A (ja) * 1993-04-30 1994-11-08 Japan Tobacco Inc ホスホリパーゼａ２阻害活性を有する新規フタルイミド誘導体
US5411741A (en) 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
GB9320113D0 (en) 1993-09-29 1993-11-17 Zeneca Ltd Tricyclic derivatives
PT732928E (pt) * 1993-12-10 2005-03-31 Merrell Pharma Inc Metodo para a reducao dos niveis de colesterol serico com 2,6-dialquil-4-sililfenois
US5426196A (en) 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
JPH07328425A (ja) * 1994-06-03 1995-12-19 Toshiba Corp プラズマ化学反応装置
US5693337A (en) 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5635514A (en) * 1994-10-25 1997-06-03 G. D. Searle & Company Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
FR2738817B1 (fr) * 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1997015546A1 (fr) * 1995-10-26 1997-05-01 Nippon Shinyaku Co., Ltd. Derives d'acide carboxylique et compositions pharmaceutiques
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
CA2271054C (en) * 1996-11-20 2005-12-13 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
WO1998030255A2 (en) 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
GB9705502D0 (en) 1997-03-17 1997-05-07 Univ Wales Swansea The Chlorination or aromatic compounds and catalysts therefor
WO1998042327A2 (en) 1997-03-24 1998-10-01 Cote Gilles Vascular remodeling agent
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
ATE304350T1 (de) * 1997-05-14 2005-09-15 Atherogenics Inc Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1017375A2 (en) 1997-09-24 2000-07-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
DE19850532A1 (de) 1998-11-03 2000-05-04 Nematel Dr Rudolf Eidenschink Bisphenylthio-Verbindungen
MXPA01004683A (es) * 1998-11-09 2002-09-18 Atherogenics Inc Metodos y composiciones para disminuir los niveles de colesterol en el plasma.
EP1133483B1 (en) 1998-11-23 2003-04-23 Janssen Pharmaceutica N.V. Il-5 inhibiting 6-azauracil derivatives
RU2306335C2 (ru) 1999-03-10 2007-09-20 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Стволовые клетки и решетки, полученные из жировой ткани
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
WO2001079164A2 (en) 2000-03-21 2001-10-25 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
AU4765101A (en) * 2000-03-21 2001-10-03 Atherogenics Inc Thioketals and thioethers for inhibiting the expression of vcam-1
US6323359B1 (en) 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
EP1385501A2 (en) * 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
WO2002092660A2 (en) 2001-05-14 2002-11-21 Omnova Soltions Inc Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups
US7187870B2 (en) * 2003-10-15 2007-03-06 Oewaves, Inc. Tunable balanced opto-electronic filters and applications in opto-electronic oscillators

Also Published As

Publication number Publication date
CA2289851C (en) 2009-03-10
IL175130A (en) 2009-02-11
DK0981343T3 (da) 2006-01-30
SK286392B6 (sk) 2008-09-05
TR199902803T2 (xx) 2000-07-21
DE69829966T2 (de) 2006-02-09
EA199901027A1 (ru) 2000-06-26
EA009987B1 (ru) 2008-04-28
WO1998051289A2 (en) 1998-11-19
SK286766B6 (sk) 2009-05-07
IL164568A0 (en) 2005-12-18
HUP0004592A3 (en) 2001-12-28
IL178072A (en) 2010-12-30
KR20080066885A (ko) 2008-07-16
EA200601059A1 (ru) 2007-02-27
HUP0004592A2 (hu) 2001-06-28
JP2001524986A (ja) 2001-12-04
US6548699B1 (en) 2003-04-15
DE69829966D1 (de) 2005-06-02
IL164568A (en) 2010-05-31
CN1275596C (zh) 2006-09-20
ID29158A (id) 2001-08-02
NO319855B1 (no) 2005-09-26
AU7571198A (en) 1998-12-08
US20020177717A1 (en) 2002-11-28
US20080214660A1 (en) 2008-09-04
CZ9904024A3 (cs) 2001-10-17
HUP0004230A3 (en) 2001-12-28
ES2241139T3 (es) 2005-10-16
AU747801C (en) 2003-01-30
US20020169215A1 (en) 2002-11-14
SK153199A3 (en) 2000-05-16
US6147250A (en) 2000-11-14
NO995544D0 (no) 1999-11-12
DK1464639T3 (da) 2007-07-09
PL194329B1 (pl) 2007-05-31
US20050090487A1 (en) 2005-04-28
NO995543D0 (no) 1999-11-12
CZ301985B6 (cs) 2010-08-25
NZ501069A (en) 2000-07-28
US7375252B2 (en) 2008-05-20
PL343904A1 (en) 2001-09-10
NZ528906A (en) 2005-06-24
EP0994853A2 (en) 2000-04-26
CN101284808A (zh) 2008-10-15
US20020188118A1 (en) 2002-12-12
NO327603B1 (no) 2009-08-31
CN1287783C (zh) 2006-12-06
ID23877A (id) 2000-05-25
HK1025947A1 (en) 2000-12-01
EA199901026A1 (ru) 2000-08-28
CN1263462A (zh) 2000-08-16
CN1977837B (zh) 2010-12-08
IL132797A0 (en) 2001-03-19
CN100453530C (zh) 2009-01-21
CZ301302B6 (cs) 2010-01-06
DE69837295D1 (de) 2007-04-19
BR9809793A (pt) 2000-06-27
HUP0004230A2 (hu) 2001-06-28
AU750041B2 (en) 2002-07-11
CN1200704C (zh) 2005-05-11
EA012847B1 (ru) 2009-12-30
PL336788A1 (en) 2000-07-17
EP0981343B1 (en) 2005-09-14
CZ9904023A3 (cs) 2001-07-11
CN1977837A (zh) 2007-06-13
EP0994853B1 (en) 2005-04-27
IL132798A0 (en) 2001-03-19
KR20070008725A (ko) 2007-01-17
KR20070007207A (ko) 2007-01-12
WO1998051289A3 (en) 1999-05-14
SK153299A3 (en) 2000-05-16
CA2289851A1 (en) 1998-11-19
CZ301183B6 (cs) 2009-12-02
KR100882335B1 (ko) 2009-02-11
CN1496739A (zh) 2004-05-19
US6602914B2 (en) 2003-08-05
JP2006232848A (ja) 2006-09-07
CN1263522A (zh) 2000-08-16
US6617352B2 (en) 2003-09-09
US7189870B2 (en) 2007-03-13
CN1977836A (zh) 2007-06-13
CZ301313B6 (cs) 2010-01-13
DE69837295T2 (de) 2007-11-15
ATE294158T1 (de) 2005-05-15
JP2002503227A (ja) 2002-01-29
EA200500249A1 (ru) 2005-06-30
EP0981343A2 (en) 2000-03-01
ES2283933T3 (es) 2007-11-01
ATE356113T1 (de) 2007-03-15
DE69831566T2 (de) 2006-06-14
KR20010012503A (ko) 2001-02-15
SK285695B6 (sk) 2007-06-07
AU747801B2 (en) 2002-05-23
CN1496740A (zh) 2004-05-19
ATE304350T1 (de) 2005-09-15
EA009370B1 (ru) 2007-12-28
NO20032254L (no) 2000-01-10
SK286674B6 (sk) 2009-03-05
KR20010012504A (ko) 2001-02-15
WO1998051662A3 (en) 2000-03-02
TR199902802T2 (xx) 2000-04-21
WO1998051662A2 (en) 1998-11-19
JP2006265257A (ja) 2006-10-05
US20020193446A1 (en) 2002-12-19
NO316221B1 (no) 2003-12-29
CA2428130A1 (en) 1998-11-19
IL178072A0 (en) 2006-12-31
ES2248901T3 (es) 2006-03-16
US6828447B2 (en) 2004-12-07
HU226611B1 (en) 2009-04-28
US6121319A (en) 2000-09-19
NO995543L (no) 2000-01-10
PT1464639E (pt) 2007-06-15
IL132798A (en) 2006-12-31
CA2292388A1 (en) 1998-11-19
AU7485198A (en) 1998-12-08
KR100953990B1 (ko) 2010-04-21
CA2292388C (en) 2004-07-20
DE69831566D1 (de) 2006-01-26
PL207885B1 (pl) 2011-02-28
EA010183B1 (ru) 2008-06-30
NO995544L (no) 2000-01-10
JP3930056B2 (ja) 2007-06-13
NO20032254D0 (no) 2003-05-19
CY1107645T1 (el) 2013-04-18
EA200800375A1 (ru) 2008-06-30
KR100919883B1 (ko) 2009-09-30
BR9809819A (pt) 2001-09-18

Similar Documents

Publication Publication Date Title
HK1024629A1 (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease.
HK1053989A1 (en) Fused pyrrolocarbazoles against inflammation
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ATE232396T1 (de) Oxydiertes thymosin beta 4
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
HUP0104963A3 (en) Compositions for the treatment of skin diseases
TR200200278T2 (tr) Kalsilitik bileşimler
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
PT951471E (pt) Inibidores cicloalquilo de farnesiltransferase de proteinas
EP1468989A3 (en) Compounds and methods for the inhibition of the expression of VCAM-1
UA25252A (uk) Хірургічhий спосіб лікуваhhя захворюваhь артерій hижhіх кіhцівок
HUP0202416A2 (hu) Új kombinációs gyógyszerkészítmény és ennek alkalmazása kardiovaszkuláris rendellenességek kezelésében
PL350327A1 (en) Compositions for the treatment of skin diseases
UA25164A (uk) Спосіб оперативhого лікуваhhя косоокості по в.і. ємчеhку
UA25165A (uk) Спосіб оперативhого лікуваhhя косоокості по в.і. ємчеhку

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100514